Join our
Investor Newsletter

To receive Investor News as it is released please sign up

News Releases

RenalytixAI Announces Podium Presentation and Publication on "Evaluation of Payer Budget Impact Associated with the Use of Artificial Intelligence in vitro Diagnostic, KidneyIntelX™, to Modify DKD Progression"

March 24, 2020
Oral presentation accepted for Late Breaking session of the National Kidney Foundation Spring Clinical Meeting Accompanying abstract accepted for publication in American Journal of Kidney Disease   NEW YORK, March 24, 2020 /PRNewswire/ --  Renalytix AI plc (LSE: RENX),  the AIM-traded developer of

Medicare Sets National Price for KidneyIntelX™

December 3, 2019
NEW YORK, Dec. 3, 2019 /PRNewswire/ --  Renalytix AI plc  (LSE: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the Centers for Medicare and Medicaid Services ("CMS") has released the Final 2020 Clinical Laboratory Fee Schedule

U.S. CPT® Code Granted for KidneyIntelX™

July 1, 2019
CPT Code a key component for reimbursement from private medical insurance and Medicare   NEW YORK, July 1, 2019 /PRNewswire/ --  Renalytix AI plc  (LON: RENX), a developer of artificial intelligence-enabled clinical diagnostics for kidney disease, announced today that the American Medical
Displaying 91 - 100 of 108